Pregabalin NDC 27808-237

NDC codes

FDA NDC Directory

Product NDC (as listed)27808-237Labeler and product segments. Claims need a package NDC.

Product NDC at billing width27808-0237Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
27808-237-01	27808023701	90 CAPSULE in 1 BOTTLE (27808-237-01)Marketed from Feb 1, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pregabalin
Generic name (nonproprietary): pregabalin
Active ingredients: Pregabalin — 100 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Tris Pharma Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214322
Marketing start: Jul 15, 2021
Listing expires: Dec 31, 2026
DEA schedule: CV
Identifiers: Product ID 27808-237_34723420-dabe-4070-83f1-5de1db603532SPL ID 34723420-dabe-4070-83f1-5de1db603532SPL set ID 62aa850d-199c-44d5-a730-45f43efa850eRxCUI 483438, 483440, 483444, 483446, 483448, 483450, 577127UNII 55JG375S6MUPC 0327808239013, 0327808237019, 0327808241016, 0327808236012, 0327808240019, 0327808235015, 0327808238016

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N427808023701 followed by a unit qualifier and the quantity

Package 27808-0237-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 30, 2022.

Indications (excerpt from the label)

Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Pregabalin is indicated for: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) • Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1 ) • Fibromyalgia ( 1 ) • Neuropathic pain associated with spinal cord injury ( 1 )…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214322

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214322
Product	Strength	Form · route	Labeler	Product NDC
Pregabalin	Pregabalin 300 mg/1	CapsuleOral	Tris Pharma Inc	27808-241
Pregabalin	Pregabalin 50 mg/1	CapsuleOral	Tris Pharma Inc	27808-235
Pregabalin	Pregabalin 75 mg/1	CapsuleOral	Tris Pharma Inc	27808-236
Pregabalin	Pregabalin 225 mg/1	CapsuleOral	Tris Pharma Inc	27808-240
Pregabalin	Pregabalin 150 mg/1	CapsuleOral	Tris Pharma Inc	27808-238
Pregabalin	Pregabalin 200 mg/1	CapsuleOral	Tris Pharma Inc	27808-239